Also found in: Dictionary, Medical, Wikipedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Synonyms for Cordarone

an antiarrhythmic drug (trade name Cordarone) that has potentially fatal side effects and is used to control serious heart rhythm problems only when safer agents have been ineffective

References in periodicals archive ?
Even for health ministry workers, the chances of finding Cordarone were similarly slim.
Sanofi-Synthelabo's potentially life-saving drug Cordarone, which is used to treat patients who suffer from certain heart conditions, was among the critical supplies that had been requested.
The bag, last seen in the early hours of Saturday, contained: 28, 75mg tablets of Aspirin; 28, 20mg tablets of Frusemide; 28, 100mg tablets of Thiamine; 38, 125mg of Digoxin; 28, 200mg tablets of Cordarone and 28, 200mg tablets of Amiodarone.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that more than 70 percent of surveyed cardiologists and 60 percent of surveyed managed care organizations' (MCOs) pharmacy directors consider amiodarone (Sanofi-Aventis's Cordarone, generics) to be the most effective antiarrhythmic drug for maintaining normal sinus rhythm (NSR) in patients with atrial fibrillation.
Amiodarone HCI injection, 50 Sicor Pharmaceuticals Cordarone IV
The parties' trial memoranda in a case holding that punitive damages were properly awarded where the manufacturer of Cordarone did not warn about the potential for permanent vision loss.
It was launched after the loss of patent protection for Sanofi-Aventis previous anti-arrhythmic drug, Cordarone (amiodarone), in the US in 2002.
One of Upsher-Smith's most recent successes dame with its class III antiarrhythmic Pacerone, which it launched in April 1998 as a generic alternative to Wyeth-Ayerst Laboratories' Cordarone.
won FDA approval for its generic version of Wyeth-Ayerst Laboratories' Cordarone, a high-volume product for ventricular fibrillation.
It was launched after the loss of patent protection for Sanofi-Aventis's previous anti-arrythmic drug, Cordarone (amiodarone) in the US in 2002.
For instance, Pacerone, the company's alternative to Wyeth-Ayerst Laboratories' Cordarone, which was introduced in May, has already garnered 28% of the market for antiarrhythmics and accounts for 7% of all new prescriptions for such drugs, according to the spokesman.
The company recently won FDA approval to market Effexor, an anti-depressant; it's awaiting approval for it's awaiting approval for Cordarone (an antiarrhythmic) and Alredase (a diabetes drug).